Twitter
Link your Twitter Account to Market Wire News
When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
CMMB - Adult Liver Diseases: The R&D Engine Drives Albireo's Long-Term Prospects.
February, 01 2022 03:20 PM
Chemomab Therapeutics Ltd.
The global launch of Bylvay was more successful than expected and Albireo doubled its net sales guidance for 2021. Beyond Odevixibat, Albireo was able to discover new drugs with blockbuster. Both early clinical assets address a market with a high medical need and have blockbuster potential with their game changing mode of action. Albireo's ability to tailor new drugs to attractive indications based on their expertise may make Albireo a relevant liver disease player. For further details see:
Adult Liver Diseases: The R&D Engine Drives Albireo's Long-Term Prospects.
Stock Information
Company Name:
Chemomab Therapeutics Ltd.
Stock Symbol:
CMMB
Market:
NASDAQ
Website:
chemomab.com
Get CMMB Alerts
News, Short Squeeze, Breakout and More Instantly...
Market Wire News is a media platform, the information on this page was provided by SeekingAlpha via Quote Media. Read our full disclaimer .